The ‘King Kong’ of Weight-Loss Drugs Is Coming

Eli Lilly’s Mounjaro could outpace Ozempic as the most powerful treatment on the market. To develop it, the drug company needed to overhaul long-held but failing practices.

 Why would Mounjaro cause body aches?.

I’ve seen a lot of posts here experiencing this and I am too as I write this. After my first 2.5mg I am SUPER sore almost to the touch all up and down my back and shoulders.

A Q&A on Tirzepatide (Mounjaro), a Novel Diabetes Drug, With the ADA’s Dr. Robert Gabbay

From A1C reduction to weight loss, these are the possible health benefits of the type 2 diabetes treatment option — which may soon become an obesity drug, too — that some experts say is a 'potential game changer.'

Diabetes drug leads to notable weight loss in people with obesity – study

Experts say the apparent effects of a weekly dose of tirzepatide are potentially game changing.

Is Mounjaro the weight-loss drug we’ve been waiting for?

Mounjaro works by mimicking two hormones that are secreted by the small intestine after you eat: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)... Both GLP-1 and GIP boost insulin levels to clear sugar from the blood, making them effective for diabetes. But they also circulate in the brain and reduce appetite by affecting how people experience “hunger or fullness or contentment between meals, thoughts of food, and cravings for food,” explained Robert Kushner, an endocrinologist at Northwestern University’s Feinberg School of Medicine in Chicago.

Mounjaro Side Effects: Understanding the Impact on Diabetes Treatment

While it offers a promising addition to diabetes care, I must emphasize that any medication comes with its own set of possible side effects. Experiencing side effects can vary greatly from person to person. Some of the common side effects reported with the use of Mounjaro include nausea, diarrhea, and reduced appetite. However, patients should be aware and vigilant as there could be more severe reactions to the drug.

Ozempic Is About to Be Old News

Like semaglutide, Mounjaro mimics the effects of GLP-1, but it also hits receptors for another hormone—GIP. That leads to even more weight loss by further attenuating focus on food and potentially also increasing the activity of a fat-burning enzyme, Tapper said. So-called dual-agonist drugs “offer a step change” in both weight loss and blood-sugar control, he added.

Ozempic Rival Mounjaro Helps Diabetes Patients Lose ‘Meaningful’ Weight, Study Shows

Diabetic participants who were overweight or obese lost up to 15.7% of body weight

The Diabetes Drug That Could Overshadow Ozempic

Another diabetes drug, called Mounjaro, is now gaining attention, with many people using it off-label to lose weight. Some research has found that Mounjaro may be even more powerful than either Ozempic or Wegovy. One major study comparing these drugs found that taking tirzepatide, the active ingredient in Mounjaro, led to sharper reductions in blood sugar levels and greater weight loss than the other drugs.

Tirzepatide, for treatment of adults with obesity, is on the fast track for FDA's OK

There are signs that obesity drugs are improving. A new drug being "fast-tracked" for FDA approval has been shown to help users lose more than a fifth of their body weight.

What to Know About Zepbound

Wegovy, Ozempic, Mounjaro, and Zepbound all promote weight loss by decreasing appetite. But while semaglutides like Ozempic and Wegovy work on one hormone — glucagon peptide 1, or GLP 1, which comes from the small intestine and regulates blood sugar and appetite — tirzepatide is unique in that it works on both GLP-1 and a second hormone, gastric-inhibitory polypeptide, or GIP, which secretes insulin. “There’s sort of a synergy between these two hormones in the gut,” says Dr. Srinath.

Why the Diabetes Drug Mounjaro Works So Well for Weight Loss

In studies Lilly submitted to the FDA, the company showed that Mounjaro—which is already approved for treating Type 2 diabetes—can lower body mass among users at its highest dose by up to 15%. While semaglutide targets one molecule, glucagon-like peptide-1 (GLP-1), involved in insulin secretion, tirzepatide is the first to target two: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).